Products
Categories

We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.

AAV●Tek AEX Buffer Screening Kit

A novel solution for full capsid enrichment

Find the ideal buffer to optimize the separation of empty and full capsids while maintaining high yields with our first-of-its-kind AAV•Tek™ AEX Buffer Screening Kit.

 

Now available for AAV2, AAV6, and AAV8, it can save months in your AAV process development at the polishing step.

AEX buffer screening kit with box

 

The AEX Buffer Screening Kit is part of our line of

end-to-end reagents for every step of your AAV workflow



Keep scrolling to learn more about how our AEX Buffer Screening Kit can save you months at the polishing step,

or explore our AAV workflow to find tailored solutions for every step of your AAV process.

 

 

workflow workflow

 

AAV•Tek™ AEX Buffer Screening Kit

 

Now available for

AAV2, AAV6, and AAV8

 

Through extensive screening, we created a first-of-its-kind kit that can help you identify the ideal buffer formulation for the separation of empty and full capsids while maintaining high yields, saving months in your process development at the polishing step.

 

Each serotype-specific kit contains paired sets of optimized equilibration and elution buffers in 1 L bottles. These discrete formulations have been proven to be effective across multiple upstream and purification platforms.

Explore the products in the kits

 

 

 

 

AAV polishing, 

simplified

With over 25 years of experience manufacturing custom buffers and a dedicated Research and Development team with expertise in the AAV bioproduction process, we can help simplify your AAV workflow.

Save months of development time

 

When you are building a new process, it requires significant investment to find the right reagents to use across your workflow. Our kit accelerates this process, saving you weeks of trial and error so you can make better use of your time and resources.

Optimize capsid separation


Effectively separate empty and full capsids. Our rigorous testing and batch-to-batch consistency help you get results you can trust. The kit has been verified for use on multiple upstream workflows, transgenes, and downstream purification platforms.

Seamless scale-up from RUO to GMP

Our scientists and engineers have the expertise to guide you through the end-to-end buffer screening process. Once you find the ideal fit for your system, we can help make further customizations and set you up with a reliable supply of your unique formulation.

See the data

To identify serotype-specific buffer formulations, we utilized a Design of Experiments (DOE) approach to define the most impactful attributes for the polishing step of your AAV purification process. These optimized buffers are designed to effectively remove empty capsids while maintaining maximum recovery and infectivity.

The process parameters evaluated for AAV full capsid enrichment include a full range of pH, elution salts, excipients, surfactants, and stabilizers/osmolytes. The DOE was executed to elucidate the extent of each contributing factor.

Explore the data by serotype

Implementation of DOE was used to determine optimal buffer conditions for this particular serotype. In vitro data has shown that effective separation of empty and full capsids can be performed using this buffer kit.

 

Alt text

Different DNA sequences that are packaged within the viral capsid may impact the pI of the overall construct. Therefore, the optimized buffer formulations were validated against multiple sequences, as shown in these figures.

 

Initial work implementing the DOE was performed using monolith technology due to the high flow rates associated with these columns. After identification of the optimal recipe, however, the formulation was validated across multiple other platforms, including two commonly used AEX resins shown in the figure below.

 

To ensure the kit is agnostic of the upstream process used (for instance, cell line, media choice, transfection and harvest conditions) and does not affect the ability to successfully utilize the buffer set, multiple processes were implemented and tested using the optimal buffer formulations.

 

Variations to the downstream processes, such as TFF, affinity, and CEX, may affect the final AEX polishing step. To probe this concern, multiple downstream processes were implemented to verify the applicability of the optimized buffer formulations.

 

The figure below demonstrates the utility of the kit for various chromatographic modalities. The buffer screening is shown using a linear gradient (left) and then finalized using an isocratic hold (right) to facilitate scale-up requirements.

 

Implementation of DOE was used to determine optimal buffer conditions for this particular serotype. In vitro data has shown that effective separation of empty and full capsids can be performed using this buffer kit.

 

Alt text

Different DNA sequences that are packaged within the viral capsid may impact the pI of the overall construct. Therefore, the optimized buffer formulations were validated against multiple sequences, as shown in these figures.

 

Initial work implementing the DOE was performed using monolith technology due to the high flow rates associated with these columns. After identification of the optimal recipe, however, the formulation was validated across multiple other platforms, including two commonly used AEX resins shown in the figure below.

 

To ensure the kit is agnostic of the upstream process used (for instance, cell line, media choice, transfection and harvest conditions) and does not affect the ability to successfully utilize the buffer set, multiple processes were implemented and tested using the optimal buffer formulations.

 

Variations to the downstream processes, such as TFF, affinity, and CEX, may affect the final AEX polishing step. To probe this concern, multiple downstream processes were implemented to verify the applicability of the optimized buffer formulations.

 

The figure below demonstrates the utility of the kit for various chromatographic modalities. The buffer screening is shown using a linear gradient (left) and then finalized using an isocratic hold (right) to facilitate scale-up requirements.

 

Implementation of DOE was used to determine optimal buffer conditions for this particular serotype. In vitro data has shown that effective separation of empty and full capsids can be performed using this buffer kit.

 

Alt text

Different DNA sequences that are packaged within the viral capsid may impact the pI of the overall construct. Therefore, the optimized buffer formulations were validated against multiple sequences, as shown in these figures.

 

Initial work implementing the DOE was performed using monolith technology due to the high flow rates associated with these columns. After identification of the optimal recipe, however, the formulation was validated across multiple other platforms, including two commonly used AEX resins shown in the figure below.

 

To ensure the kit is agnostic of the upstream process used (for instance, cell line, media choice, transfection and harvest conditions) and does not affect the ability to successfully utilize the buffer set, multiple processes were implemented and tested using the optimal buffer formulations.

 

Variations to the downstream processes, such as TFF, affinity, and CEX, may affect the final AEX polishing step. To probe this concern, multiple downstream processes were implemented to verify the applicability of the optimized buffer formulations.

 

The figure below demonstrates the utility of the kit for various chromatographic modalities. The buffer screening is shown using a linear gradient (left) and then finalized using an isocratic hold (right) to facilitate scale-up requirements.

 


Our collaboration with 
Sartorius BIA Separations

 

Our collaborative research shows the successful achievement of over 85% full AAV capsid enrichment with 80-90% recoveries when pairing optimized equilibration and elution buffers from our AAV•Tek AEX Buffer Screening Kit with Sartorius BIA Separations' BIA CIMmultus® QA monolith at the polishing step, given a specific starting material of AAV8 that contained 46% full capsids.

 

Watch our webinar to see the detailed results of the study.

THE POWER OF PARTNERSHIP

Working together to
make solutions possible

“Our collaboration with Teknova has demonstrated two essential components for the successful separation of AAV empty and full capsids during the downstream polishing step: the purification platform and the buffer composition. By combining our strengths, we’ve been able to consistently reproduce results that indicate the use of Teknova’s high-quality, custom buffer formulations with our CIMmultus QA monolith increases the yield and purity of full AAV particles.”

 

- Aleš Štrancar, Managing Director at Sartorius BIA Separations

 

 

HOW IT WORKS

The protocol

These instructions will guide you through the process of using the AEX Buffer Screening Kit so you can get optimal results. Have a question? We're here to help. Drop us a line at research@teknova.com or call 1.800.209.4488.

What's next

From screening to scale-up

Our AEX Buffer Screening Kit sets you up to scale for commercial production. It addresses a key challenge for gene therapy manufacturing by identifying the optimal buffer for the removal of empty capsids from the therapeutic product while still maintaining high yields.

 

After using the kit to select the buffer that best fits your specific application, consult with our team to get set up to scale. We can help make further customizations as needed and assist with GMP-compliant manufacturing.

TAKEAWAY

Product guide

Here's a quick reference sheet with all the key information
about our AEX Buffer Screening Kits for AAV2, AAV6, and AAV8.

AAV•TEK SOLUTIONS

Coming soon: AAV5 and AAV9

We are in the process of developing screening solutions for additional serotypes, including AAV5 and AAV9. Get in touch below to join the waitlist, or to let us know about other serotypes you are working with to help us prioritize our future developments.

 

If you are working with a custom or modified AAV, we may also be able to run a DOE for your specific serotype.

The people behind our novel products

Meet the AAV team

Our AAV•Tek Solutions are designed by our dedicated Research and Development team as part of our initiative to invest in the discovery of novel products designed to give you a competitive advantage in your work.

 

With custom manufacturing capabilities that fit seamlessly into your cell and gene therapy workflow and our in-house scientific expertise, we can be a true partner to you, helping you overcome bioprocessing challenges and accelerate your breakthroughs.

Group shot of the research and development team

Frequently asked questions

The AAV•Tek AEX Buffer Screening Kit helps with a critical step in the AAV downstream purification process: the anion-exchange (AEX) polishing, or empty capsid removal, step. The kit includes a selection of AAV serotype-specific equilibration and elution buffers that have been optimized to help you save weeks to months in defining the right AEX buffers for your process.

The buffers have been developed by monitoring four different critical quality attributes (CQAs): purity, recovery, infectivity, and peak separation. Depending on your end application, some buffers may be more suitable based on the CQAs for your intended use. For each serotype-specific kit we’ve selected the optimal number of buffers to help you quickly find the best buffer for your application.

We currently offer AAV•Tek AEX Buffer Screening Kits for 2 serotypes: AAV2 and AAV8. We are working on solutions for further AAV serotypes, including AAV5, AAV6, and AAV9. If you are working with other serotypes and are interested in the kit, get in touch and let us know your serotype to help us prioritize our future developments.

The AAV•Tek AEX Buffer Screening Kits have been optimized for standard AAV serotypes containing a selection of genes of interest. Depending on the extent of modifications from the standard serotype, the buffers in the kits may or may not be suitable. Contact our experts for a consultation. We may be able to run a DOE for your specific serotype.

Each kit is optimized for a specific serotype, and the number of equilibration and elution buffers provided in the kits varies based on the requirements of that serotype. The AAV2 kit includes 7 pairs of buffers (14 bottles total) and the AAV8 kit has 6 (12 bottles total). Each buffer is supplied in a 1 L quantity. Once you have found your formulation, we can produce it in larger quantities to support your scale up.

The equilibration and elution buffers included in the kits are designed to work in specific pairings based on their compositions. We do not recommend mixing the number associated with the “A” and “B” components.

We recommend starting with the complete kit to define the best buffer set for your viral capsid. However, individual bottles of equilibration and elution buffers can be purchased separately for additional experiments and scale up.

All buffers included in the screening kits contain raw materials that are compatible with scale up and GMP manufacturing. Once you have identified the equilibration and elution buffers that work best for your process, we can help make further customizations as needed and manufacture your unique formulation in larger quantities, up to 200 L bags.

Our kits are manufactured to the same rigorous standards as all our products. All the buffers in the kit are endotoxin tested (<0.5 EU/mL) and have tight pH specifications (± 0.05). We also test and report conductivity, osmolality, density, and sterility on the Certificate of Analysis.

Yes. The kit is developed for use in a linear gradient modality to identify the best buffer for your needs, however, each buffer can be adapted for use in isocratic or step elution modalities if that is necessary for your manufacturing process. We’ll partner with you to determine the optimal formulation from the screening kit for the next steps in your scale up process. Once you've identified the step elution or isocratic hold buffers that work best for your process, we can manufacture your capsid-specific buffers in the quantities you need.

We screened hundreds of parameters to develop the serotype-specific buffers included in the kits. While the formulations of the specific buffers in our AEX Buffer Screening Kits are proprietary to Teknova, once you are ready to scale up and use GMP versions of your ideal buffers, we will share the formulations with you under our non-disclosure supply agreement. 

If the pre-AEX step eluate has a conductivity below 5.5 mS/cm?

 

Dilute the pre-AEX step eluate with 10-fold dilution of the AEX A (Equilibration) Buffer, verify that the conductivity is no more than (NMT) 5.5 mS/cm, and adjust/verify that the pH is ± 0.1 of the AEX A (Equilibration) Buffer. Remeasure conductivity if a pH adjustment was required and verify that it is NMT 5.5 mS/cm. 
 

If the pre-AEX step eluate has a conductivity greater than 5.5 mS/cm?

 

  • Option 1. Dilute the pre-AEX step eluate with 17 to 20-fold or possibly more (e.g., 25-fold) with AEX A (Equilibration) Buffer, verify that the conductivity is no more than (NMT) 5.5 mS/cm, and adjust/verify that the pH is ± 0.1 of the AEX A (Equilibration) Buffer. Remeasure conductivity if a pH adjustment was required and verify that it is NMT 5.5 mS/cm.

 

  • Option 2. If Option 1 doesn’t reduce the conductivity enough, adjust conductivity with a non-salt containing buffer with a pH ± 0.1 of the AEX A (Equilibration) Buffer, verify that the conductivity is no more than (NMT) 5.5 mS/cm, and adjust/verify that the pH is ± 0.1 of the AEX A (Equilibration) Buffer. Remeasure conductivity if a pH adjustment was required and verify that it is NMT 5.5 mS/cm.

Find out what’s possible

 

Talk to our consultants today to discover custom solutions that can help you achieve your goals.

 

Get in touch:

1.800.209.4488

Monday to Friday

8:00AM–5:00PM PT

Contact us button